Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.

Ann Hematol · 2023 · PMC9889492 · PMID 36564535

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Furthermore, in our trial, RUX also showed a strong trend towards reduction of patient-reported night sweats, while patient-reported bone pain, an additional common symptom in PV pts [ 4 ], scores remained unaltered.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.